Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Antoniou

Showing results (281-290 of 395) with videos related to

Pageof 40
Sort By:
Breast Cancer Research : BCR|February 28, 2020
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriersNasim Mavaddat, Antonis C Antoniou, Thea M Mooij, et al.
Breast Cancer Research : BCR|January 18, 2020
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriersNasim Mavaddat, Antonis C Antoniou, Thea M Mooij, et al.
JNCI Cancer Spectrum|July 31, 2019
Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort StudyLieske H Schrijver, Håkan Olsson, Kelly-Anne Phillips, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsHongyan Li, Christoph Engel, Miguel de la Hoya, et al.
Breast Cancer Research and Treatment|December 17, 2008
No evidence that GATA3 rs570613 SNP modifies breast cancer riskSharon E Johnatty, Fergus J Couch, Zachary Fredericksen, et al.
JAMA|June 21, 2017
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersKaroline B Kuchenbaecker, John L Hopper, Daniel R Barnes, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 28, 2010
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriersChristoph Engel, Beatrix Versmold, Barbara Wappenschmidt, et al.
British Journal of Cancer|August 27, 2009
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersO M Sinilnikova, A C Antoniou, J Simard, et al.
British Journal of Cancer|March 24, 2011
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2A Osorio, R L Milne, R Alonso, et al.
NPJ Breast Cancer|February 19, 2025
Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancerReiner Hoppe, Stefan Winter, Wing-Yee Lo, et al.
Pageof 40

Showing results (281-290 of 395) with videos related to

Sort By:
Pageof 40
Breast Cancer Research : BCR|February 28, 2020
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriersNasim Mavaddat, Antonis C Antoniou, Thea M Mooij, et al.
Breast Cancer Research : BCR|January 18, 2020
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriersNasim Mavaddat, Antonis C Antoniou, Thea M Mooij, et al.
JNCI Cancer Spectrum|July 31, 2019
Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort StudyLieske H Schrijver, Håkan Olsson, Kelly-Anne Phillips, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsHongyan Li, Christoph Engel, Miguel de la Hoya, et al.
Breast Cancer Research and Treatment|December 17, 2008
No evidence that GATA3 rs570613 SNP modifies breast cancer riskSharon E Johnatty, Fergus J Couch, Zachary Fredericksen, et al.
JAMA|June 21, 2017
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersKaroline B Kuchenbaecker, John L Hopper, Daniel R Barnes, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 28, 2010
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriersChristoph Engel, Beatrix Versmold, Barbara Wappenschmidt, et al.
British Journal of Cancer|August 27, 2009
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersO M Sinilnikova, A C Antoniou, J Simard, et al.
British Journal of Cancer|March 24, 2011
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2A Osorio, R L Milne, R Alonso, et al.
NPJ Breast Cancer|February 19, 2025
Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancerReiner Hoppe, Stefan Winter, Wing-Yee Lo, et al.
Pageof 40